Omiga 3
Phase 1Small molecule
Omiga 3 is one of 24 small molecule programs targeting Lower Urinary Tract Symptom. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Lower Urinary Tract Symptom
#DrugCompanyPhaseTrials
1Flomax
SanofiApproved
Cialis
Eli LillyApproved
Vesicare
AstellasApproved
Myrbetriq
AstellasApproved
Rapaflo
AbbVieApproved
Livial
PfizerApproved
Lioresal
NovartisApproved
Uroxatral
AAdvanz Pharma
Approved
Detrol La
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Tolterodine ER
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lower Urinary Tract Symptom1 trial
Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate
Not yet recruiting·—·Phase 1·NCT07466030·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Omiga 3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAssiut University